Today we welcome Dr. Daniel Vitt, CEO of Immunic Therapeutics.

With World MS Day being tomorrow, the 30th of May, this is the perfect moment to focus on multiple sclerosis — a disease that affects nearly three million people worldwide and still leaves many patients searching for better options.

In today’s episode Daniel shares his own journey into biotechnology, walk us through what life with MS really looks like for patients, and explain the science behind Immunic’s most advanced program, IMU-838. We discuss what makes Immunic’s oral therapy different from today’s treatments, uncover the latest data from the CALLIPER and ENSURE trials, and talk about what the future of MS care could look like.

• 01:22 Meet Daniel Vitt
• 04:54 Understanding multiple sclerosis
• 07:53 Evolution of the MS treatment landscape
• 12:08 Immunic’s lead MS therapy explained
• 22:57 World MS Day and what's next for Immunic

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

To dive deeper into the topic:

• 11 neuroscience biotech companies you should know about
• The emergence of BTK inhibitors in multiple sclerosis treatment: Companies close in on approval
• Six biotech companies advancing multiple sclerosis therapies

Today I am welcoming two guests: Quin Wills, CEO of Ochre Bio, a biotech developing RNA therapies for chronic liver disease using AI models, and Stéphane Barges, CEO of Lexogen, an RNA transcriptomics company and NGS service provider. It’s a deep dive into cutting edge transcriptomics, human-first data, and artificial intelligence.

00:55: The challenges of liver disease

04:44: How Lexogen supports NGS drug discovery

07:29: Major transcriptomics developments

10:05: Designing high quality AI data

15:47: How the Ochre-Lexogen partnership began

17:17: Why a specialist partner is essential for scale

18:21: Lexogen delivers on the massive sequencing project

21:50: Why high quality data is crucial

27:02: Lexogen's role in AI discovery

34:51: Future plans and directions

This episode was produced with the support of Lexogen. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

To dive deeper into the topic:

• Deep phenotyping brings accuracy to precision medicine
• Spatial Transcriptomics: A window into disease
• Spatial Transcriptomics Landscape Shifts With Two Major Acquisitions

Today, we're digging into a topic that's getting a lot more attention lately, how early decisions in cell therapy end up shaping or complicating everything that comes later. Our episode today is Freeze Variability, Not Progress, How to Strengthen Your Cell Therapy Supply Chain from the Start, and we're going to challenge a few long-held beliefs about how starting material should be handled.

My guest today is Dominic Clarke, Vice President of Technical Operations for IntegriCell at Cryoport Systems. Dominic has spent years in the trenches building and scaling cell therapy processes from early development through commercialization. So, he's seen where things break and what actually works. I hope you enjoy my conversation with Dominic Clark.

• 01:07 Meet Dominic Clarke and Cryoport Systems
• 06:24 Fresh cells versus frozen cells
• 08:21 Why teams switch to cryopreservation late
• 12:37 The challenge of variability
• 16:47 IntegriCell when you already have a process in place
• 22:17 An argument for cryopreservation based on data
• 25:56 The future of IntegriCell and Cryoport Systems

This episode is brought to you with the support of Cryoport Systems.

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

To dive deeper into the topic:

• IntegriCell® Cryopreservation
• Cryoport Systems on the state of the ATMP market and the importance of supply chain resilience
• Cracking the code: Delivering biotherapeutics successfully across EMEA